Oncothyreon appoints ZymoGenetics' CEO to its board
This article was originally published in Scrip
The US biotechnology company Oncothyreon has appointed Dr Douglas Williams to its board of directors. Dr Williams is CEO of the biopharmaceutical company ZymoGenetics; he previously held senior positions at Seattle Genetics, Immunex and Amgen. Last December, Oncothyreon announced it was restructuring to focus on small molecules, after being threatened with a Nasdaq delisting in September 2008 for failing to meet a minimum $50 million market value for 10 consecutive days (scripnews.com, December 22nd, 2008). It has since made a number of new senior appointments, including Dr Scott Peterson as vice-president of R&D and Dr Diana Hausman as vice-president of clinical development.